Vorinostat Completed Phase 1 Trials for Leukemias / Small Intestine Cancer / Unspecified Adult Solid Tumor, Protocol Specific / Multiple Myeloma and Plasma Cell Neoplasm / Malignant Lymphomas / Prostate Cancer Treatment

IndicationsStatusPurposePhase
CompletedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT00561418Vorinostat After Stem Cell Transplant in Treating Patients With High-Risk Lymphoma
NCT01169532Ridaforolimus and Vorinostat in Treating Patients With Advanced Solid Tumors or Lymphoma
NCT00127140A Study of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Malignant Lymphoma (0683-030)
NCT00227513Vorinostat and Bortezomib in Treating Patients With Metastatic or Unresectable Solid Tumors
NCT00771472Vorinostat (MK-0683) Phase I Study in Cutaneous T-Cell Lymphoma (CTCL) Patients (MK-0683-089 EXT1)
NCT00324480Vorinostat and Alvocidib in Treating Patients With Advanced Solid Tumors
NCT00287937Vorinostat, Paclitaxel, and Carboplatin in Treating Patients With Advanced or Refractory Solid Tumors
NCT00243100Vorinostat and Gemcitabine in Treating Patients With Metastatic or Unresectable Solid Tumors
NCT00816283Dasatinib and Vorinostat in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia
NCT00005634Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy
NCT01421173Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies
NCT01276717Study of Carfilzomib and Vorinostat for Relapsed or Refractory Lymphoma
NCT00331955Vorinostat and Doxorubicin in Treating Patients With Metastatic or Locally Advanced Solid Tumors
NCT00121277Vorinostat and Capecitabine in Treating Patients With Metastatic or Unresectable Solid Tumors